全身免疫炎症指数与替诺福韦乙肝母婴阻断效果的关系

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (2323 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the relationship between systemic immune inflammatory index (SII) and the blocking effect of tenofovir (TDF) on hepatitis B. Methods This was a retrospective, single-center study. From June 2019 to June 2023, 148 pregnant women infected with hepatitis B virus (HBV) were recruited from our hospital. The HBV DNA load, HBeAg positive cases, baseline neutrophils, baseline SII, and the number of CD4⁺T cells of neutrophils at delivery were detected. The HBsAg and anti -HBs results of infants born after tenofovir treatment were compared, and the blocking effect of systemic inflammatory immune index and tenofovir was judged. The failure of TDF to block MTCT was defined as HBsAg positive at 6 months old. Infant immune failure is defined as the level of anti-HBs antibody < 10 IU/L at 6 months old. Results Among 148 infants evaluated at 6 months, 6 infants were found to be HBsAg positive. Compared with the HBsAg negative infant group, the HBV DNA load, HBeAg positive cases, baseline neutrophils, baseline SII, neutrophils and SII at delivery in the HBsAg positive infant group increased significantly, and CD4⁺T cells decreased significantly at delivery. Both baseline SII and SII at delivery were positively correlated with HBV DNA load at delivery (r=0.320 and 0.201, both P< 0.05), and the baseline SII was negatively correlated with baseline CD4⁺T cells (r=-0.183, P=0.026). Binary logistic regression analysis showed that baseline SII (OR=1.003, 95%CI 1.000-1.007) was an independent influencing factor of HBV infection in infants (P=0.044).132 cases (88%) of 6-month-old infants had anti-HBs antibody titers ≥ 10 IU/L. Compared with the successful infant immunization group, the baseline SII of the failed infant immunization group increased significantly. Conclusion The use of TDF in pregnant women infected with HBV can effectively block MTCT, and the increase of baseline SII level in pregnant women may be an important factor leading to the failure of TDF blocking.

Key words： systemic immune inflammatory index tenofovir hepatitis b mother to child transmission pregnant woman

Received: 24 April 2024

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Xiaodong
	REN Zhifei

Cite this article:

LIU Xiaodong,REN Zhifei. Relationship between systemic inflammatory immune index and blocking effect of tenofovir of hepatitis B from mother to child[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(4): 87-92.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I4/87

[1] LIU Z, LIN C, MAO X, et al.Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people[J]. Gut, 2023, 72(12): 2354-2363.
[2] WANG J, HUANG Y, ZENG Y, et al.Epidemiological and clinical profile of pediatric hepatitis B virus infections in Wuhan: a retrospective cohort study[J]. BMC Pediatr, 2023, 23(1): 636.
[3] SAMADI KOCHAKSARAEI G, SHAHEEN A A, SEOW C H, et al.Tenofovir disoproxil fumarate therapy to prevent hepatitis B virus vertical transmission—A review of maternal and infant outcomes[J]. Liver Int, 2022, 42(8): 1712-1730.
[4] TAN M, BHADORIA A S, CUI F, et al.Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(2): 106-119.
[5] YIM H J, KIM J H, PARK J Y, et al.Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop[J]. Clin Mol Hepatol, 2020, 26(4): 411-429.
[6] LIU J, CHEN T, CHEN Y, et al.2019 Chinese clinical practice guidelines for the prevention of mother-to-child transmission of hepatitis b virus[J]. J Clin Transl Hepatol, 2020, 8(4): 397-406.
[7] LEE Y S, BANG S M, LEE Y S.Benefits and risks of antiviral treatment during pregnancy in patients with chronic hepatitis B[J]. J Clin Med, 2021, 10(11): 2320.
[8] CHEN R, ZOU J, LONG L, et al.Safety and efficacy of tenofovir alafenamide fumarate in early-middle pregnancy for mothers with chronic hepatitis B[J]. Front Med, 2022, 8: 796901.
[9] LIU Y, LIU J, LIU L, et al.Association of systemic inflammatory response index and pan-immune-inflammation-value with long-term adverse Cardiovascular events in ST-Segment Elevation myocardial infarction patients after primary percutaneous coronary intervention[J]. J Inflamm Res, 2023, 16: 3437-3454.
[10] BELOPOLSKAYA M, AVRUTIN V, KALININA O, et al.Chronic hepatitis B in pregnant women: Current trends and approaches[J]. World J Gastroenterol, 2021, 27(23): 3279-3289.
[11] FUNK A L, LU Y, YOSHIDA K, et al.Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2021, 21(1): 70-84.
[12] FOFANA D B, SOMBORO A M, MAIGA M, et al.Hepatitis B virus in west african children: systematic review and meta-analysis of HIV and other factors associated with hepatitis B Infection[J]. Int J Environ Res Public Health, 2023, 20(5): 4142.
[13] LI B, LIU Z, LIU X, et al.Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load[J]. Hepatol Int, 2021, 15(5): 1103-1108.
[14] DING Y, CAO L, ZHU L, et al.Efficacy and safety of tenofovir alafenamide fumarate for preventing mother‐to‐child transmission of hepatitis B virus: a national cohort study[J]. Aliment Pharmacol Ther, 2020, 52(8): 1377-1386.
[15] LEE Y S, LEE H S, KIM J H, et al.Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis[J]. Korean J Intern Med, 2021, 36(1): 76.
[16] JIANG M, ZHU B, YAO Q, et al.Anti-HBs levels in children under the age of two years born to HBV carrier mothers after immunoprophylaxis: a multicenter cross-sectional study[J]. BMC Pediatr, 2021, 21(1): 492.
[17] WANG M, RAN R, ZHU Y, et al.Comparison of tenofovir disoproxil fumarate and telbivudine in preventing hepatitis B transmission in mothers with high viral load[J]. Int J Gynaecol Obstet, 2023, 160(2): 646-652.
[18] LE BERT N, GILL U S, HONG M, et al.Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection[J]. Gastroenterology, 2020, 159(2): 652-664.
[19] SHARIATI M.Impedimetric biosensor for monitoring complementary DNA from hepatitis B virus based on gold nanocrystals[J]. Journal of The Electrochemical Society, 2021, 168(1): 016512.
[20] GUO WP, LI Y, LI LB, et al.Predictive value of preoperative inflammatory indexes for postoperative early recurrence of hepatitis B-related hepatocellular carcinoma[J]. Front Oncol, 2023, 13: 1142168.
[21] QUITT O, LUO S, MEYER M, et al.T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice[J]. J hepatol, 2021, 75(5): 1058-1071.